On November 17th, specialists from the Netherlands, the United Kingdom, and Michigan discussed their methods for achieving very high levels of active monitoring during a webinar hosted by the Active Surveillance Coalition.

 

Although active surveillance has been shown to prevent prostate cancer overtreatment, most nations still neglect it. According to American models, cost-effective prostate cancer screening requires more widespread active monitoring.

 

Facts About Prostate Cancer

 

Men throughout the world get prostate cancer. With 1.3 million new cases and 358,989 deaths annually, it is the second most common male malignancy after lung cancer. The American Cancer Society predicts that there will be 268,000 cases of prostate cancer diagnosed in the United States in 2022, an increase of 20,000 cases from 2021.

 

Men with low-risk prostate cancer were often treated aggressively with radiation or surgery until recently (over the past decade). Both are effective in curing low-risk prostate cancer but come with substantial risks, including urinary issues and erectile dysfunction that can last a lifetime- it’s where Active Surveillance (AS) comes in. 

 

What is Active Surveillance For Prostate Cancer?

 

Active surveillance is a treatment option for low-grade, slowly developing prostate cancer patients. This entails keeping an eye on prostate cancer (while still confined) until the doctor determines that more aggressive therapy is necessary to stop the illness.

 

Low-risk prostate cancer managed conservatively has an excellent prognosis. Clinicians and patients should have this conversation because many men with low-risk prostate cancer can avoid the harmful effects of therapy.

 

Sweden- The World Leader In Active Surveillance

 

Prostate cancer is nearly as common in Sweden as in the United States, with an incidence rate of 103 per 100,000 people Vs. 104. Although the idea of AS was first established in North America around 30 years ago, roughly a decade before Sweden adopted it, the implementation of the gentler, kinder AS method is hugely different between the two countries.

 

When comparing the national rates of AS adoption in males with low-risk prostate cancer, Sweden’s is 94%, whereas the U.S. average is 60%. Sweden’s stats come from its well-regarded national statistics system. Expert estimates are used for the U.S. figures. 

 

According to Ola Bratt, MD, a prominent Swedish urological surgeon and a University of Gothenburg professor of clinical cancer epidemiology, 100% of males in various Swedish counties are on board with AS. About a third to half of the men in AS will quit the program during the first five years, and the main reasons are disease progression or the emotional toll of coping with any form of illness.

 

Under the microscope, the pattern of low-risk prostate cancer in men is defined as Gleason 3+3=6. The Gleason scale uses visual patterns to assess the aggressiveness of cancer. No longer is cancer diagnosed with Gleason scores below 5. More severe forms of the disease range from Gleason 7 to Gleason 10. However, less than 20% of men with a Gleason score of 3+4 take AS.

 

Sweden (and Canada) and the United States have different surgical cultures, which is still another point of differentiation. Like a carpenter learns to use a hammer and saw, surgeons receive specialized training to do their chosen field of work and experts refer to this as the “tool rule.”

 

What’s The Reason For This Difference Between The U.S. And Sweden?

 

Many factors contribute to the fact that the United States has a far lower adoption rate for AS than Sweden does:

 

  • In Sweden, everyone has access to a publicly financed healthcare system, but in the U.S., men with this form of cancer are often diagnosed around age 66 and are covered by either private insurance or Medicare.

 

  • In Sweden, urologists throughout the public health system get compensated the same whether they operate on a man or monitor his AS, reducing the financial motivation to treat the condition.

 

  • Motivators play a significant role. Up to 80% AS acceptance has been reported by urologists working in academic practices and numerous V.A. facilities. (Despite this, several V.A. hospitals have reported extremely low acceptance rates for AS. (It’s like counting down from zero.) About 10% of Swedes have private health coverage to get in to visit doctors more quickly.

 

  • The lowest adoption of AS in Sweden is in the capital city of Stockholm, at around 85%; nonetheless, this is still significantly higher than U.S. statistics. Urologists in Sweden do not earn financially from doing prostate cancer surgeries. This doesn’t mean that urologists in the United States prioritize profits over patient welfare, but it impacts aggregate data.

 

Medical experts in the U.S. and Sweden recommend that all men who have been told they have prostate cancer should seek a second opinion immediately. A decade or a single day may effectively change a person’s prostate cancer prognosis. 

 

For more info, get in touch with MyCancerJourney via this Online Form, and we will get back to you within the shortest possible time.

AA patients are more comfortable working with providers of the same race. Still, only about 3% of US oncologists are Black, reducing participation during medical visits. Providers believed AAs care could be improved by increasing cultural sensitivity through education and training initiatives and increasing staff diversity. A recent study indicated a need to develop new to increase awareness of EOL care options for underrepresented minorities.

This is underscored by the fact that prognostic estimates and treatment decision-making in cancer care are primarily based on clinical trials and statistics published by the National Cancer Institute and the American Cancer Society. Both data sets suffer from low participation by ethnic and racial minorities, even though members of these groups generally experience disproportionately higher mortality rates relative to the entire US population. The lack of widespread participation in clinical trials thus leads to problems in the scientific quality of the research, generalizability of the results, and speed of scientific discovery.

 

What can we do about it?

MyCancerJourney empowers newly diagnosed cancer patients with information tailored to their unique characteristics, clinical condition, and goals for care. MyCancerJourney combines personalized, high-tech analytics based on millions of real-world patients with the human touch of board-certified cancer support professionals to help you make informed care decisions.

 

First, our data sets reflect millions of patients, including those not included in clinical trials and individuals with other health issues common in minority groups, such as diabetes and heart disease. With this information, we can personalize treatment to minority patients.

 

Having the information is the first step; relating it to the individual makes the real difference. We can match patients with cancer with board-certified patient navigators of the same race to share information and provide support from a human perspective. When patients are provided information and support, they can better understand their treatment options and better advocate for resources available to them, such as genetic counseling and testing referrals.

 

The final step is awareness. Patients deserve to know this information and that support is available to them. MyCancerJourney provides answers to some of the most critical questions patients with cancer ask. Its groundbreaking data platform leverages the largest cancer outcomes dataset of its kind, offering the most comprehensive information available.  Get in touch with MyCancerJourney via Online, and we will get back to you within the shortest possible time.

 

References:

  1.  Smith AK, McCarthy EP, Paulk E, et al. Racial and ethnic differences in advance care planning among patients with cancer: impact of terminal illness acknowledgment, religiousness, and treatment preferences. J Clin Oncol. 2008;26:4131–4137. [PMC free article] [PubMed] [Google Scholar]
  2. Special Editions Volume 30, Issue 3S.” Scientific American, Scientific American, https://www.scientificamerican.com/magazine/special-editions/2021/special-editions-volume-30-issue-3s/

The LIVESTRONG Cancer Institutes of the Dell Medical School to Present at Clinical Congress 2019

Title of the panel: Reading Between the (Guide)-Lines: Can Real-World Survival Data Identify Patients Whose Survival Isn’t Improved by Guidelines-Based Treatments?

AUSTIN, TEXAS August 14, 2019

POTENTIAMETRICS, an Austin, TX-based healthcare data and analytics company, has been selected by the Employer Health Innovation Roundtable (EHIR) to present to 60 of the nation’s biggest employers uniting to fight the healthcare status quo.

PotentiaMetrics was selected from a pool of more than 200 innovator submissions as one of the top 10 innovators to present at the fall 2019 EHIR meeting Cohorts 1 (hosted by Best Buy) and 3 (hosted by The Home Depot).

Employer Health Innovation Roundtable (EHIR) is a coalition of the largest and most progressive employers committed to accelerating the adoption of innovation and improving employee health, wellness, and productivity. EHIR has been providing a streamlined innovation process and valuable insights to leading employers for the last 5 years.

“We are honored to be selected to present our MyCancerJourney platform to some of the largest and most innovative employers in the country,” says Robert Palmer, CEO of PotentiaMetrics.

About PotentiaMetrics 
PotentiaMetrics develops unique outcomes and insights solutions to support more informed, value-based treatment decisions that lead to better outcomes and reduced costs.

To learn more about PotentiaMetrics, visit: http://www.potentiametrics.com 
To learn more about MyCancerJourney, visit: http://www.mycancerjourney.com

AUSTIN, TEXAS (PRWEB) OCTOBER 22, 2018

PotentiaMetrics, an Austin, Texas, based healthcare data and artificial intelligence company, announced it has partnered with OptiMed Specialty Pharmacy to launch MyCancerJourney, a shared decision-making platform for cancer treatments.

MyCancerJourney was developed by researchers at Washington University School of Medicine in St. Louis to provide patient-specific survival estimates and improve cancer patient outcomes.

OptiMed’s clients will be able to enhance the value of their oncology care by offering this personalized medical information platform for their patients. Patients will have the ability to make better decisions with their healthcare providers and have a better experience with their cancer treatment journey.

“We’re excited to include this innovative platform (MyCancerJourney) to our arsenal of tools used to improve patient outcomes and add value to the healthcare ecosystem. I have seen a lot of analytical and AI healthcare solutions but MyCancerJourney is one of the very few solutions that lives up to the hype,” says OptiMed CEO Andy Reeves.

“We are thrilled to work alongside OptiMed. Both of our companies are focused on personalized approaches to healthcare that lead to improved outcomes and better value. Together we will provide the personalized information to patients and address the high-cost of cancer treatment in a meaningful way,” says Robert Palmer, CEO of PotentiaMetrics.

About PotentiaMetrics

PotentiaMetrics develops unique outcomes and insights solutions to support more informed, value-based treatment decisions that lead to better outcomes and reduced costs.

To learn more about PotentiaMetrics, visit: http://www.potentiametrics.com 
To learn more about MyCancerJourney, visit: http://www.mycancerjourney.com

About OptiMed Specialty Pharmacy

OptiMed Specialty Pharmacy, based in Kalamazoo, Michigan; is dually accredited by the Accreditation Commission for Health Care (ACHC) and URAC, specializes in treatments for rare and chronic conditions, such as rheumatoid arthritis, psoriasis, multiple sclerosis, oncology, and more. The organization has decades of experience offering personalized solutions that bring meaningful value to stakeholders.

To learn more about OptiMed Specialty Pharmacy, visit: http://www.optimedspecialtyrx.com

  Resources

Posted by PotentiaMetrics

AUSTIN, TEXAS (PRWEB) MARCH 18, 2019

POTENTIAMETRICS, an Austin, TX-based healthcare data and analytics company, announced the formation of The MyCancerJourney Clinical Advisory Board (CAB).

“We are pleased to commission the CAB and begin work to deploy the MyCancerJourney platform to improve outcomes for patients with cancer, enhance quality of life and lower costs significantly for patients, self-insured employers and the U.S. healthcare system”, noted Kendall Qualls, Chief Commercial Officer for PotentiaMetrics. He continued by saying, “over the next several weeks we’ll introduce the stellar group of physicians, surgeons, researchers that were eager to join our efforts to empower and dramatically change how patients with cancer make decisions about their treatment.

About PotentiaMetrics 
PotentiaMetrics develops unique outcomes and insights solutions to support more informed, value-based treatment decisions that lead to better outcomes and reduced costs.

To learn more about PotentiaMetrics, visit: http://www.potentiametrics.com 
To learn more about MyCancerJourney, visit: http://www.mycancerjourney.com